De Grau, GuillermoMallandrich Miret, MireiaSosa Díaz, Lilian ElisaEspinoza, Lupe CarolinaCalpena Campmany, Ana CristinaBozal de Febrer, NúriaRodríguez Allué, Manuel JoséGarduño Ramírez, María Luisa del CarmenRincón, María2025-01-272025-01-272024-051999-4923https://hdl.handle.net/2445/217998Recently, the number of people acquiring tattoos has increased, with tattoos gaining significant popularity in people between 20 and 40 years old. Inflammation is a common reaction associated with tattooing. The purpose of this study was to evaluate a nanostructured lipid carrier loading pranoprofen (PRA-NLC) as a tattoo aftercare formulation to reduce the inflammation associated with tattooing. In this context, the in vitro drug release and the ex vivo permeation-through-human-skin tests using Franz cells were appraised. The tolerance of our formulation on the skin was evaluated by studying the skin’s biomechanical properties. In addition, an in vivo anti-inflammatory study was conducted on mice skin to evaluate the efficacy of the formulation applied topically after tattooing the animals. PRA-NLC showed a sustained release up to 72 h, and the amount of pranoprofen retained in the skin was found to be 33.48 µg/g/cm2. The formulation proved to be well tolerated; it increased stratum corneum hydration, and no signs of skin irritation were observed. Furthermore, it was demonstrated to be non-cytotoxic since the cell viability was greater than 80%. Based on these results, we concluded that PRA-NLC represents a suitable drug delivery carrier for the transdermal delivery of pranoprofen to alleviate the local skin inflammation associated with tattooing.643 p.application/pdfengcc-by (c) De Grau, G. et al., 2024http://creativecommons.org/licenses/by/4.0/Malalties de la pellLípidsNanopartículesTatuatgesSkin diseasesLipidsNanoparticlesTattooinginfo:eu-repo/semantics/article7485612025-01-27info:eu-repo/semantics/openAccess